Gilder Gagnon Howe & Co. LLC Raises Holdings in Glaukos Co. (NYSE:GKOS)

Gilder Gagnon Howe & Co. LLC increased its position in Glaukos Co. (NYSE:GKOS) by 25.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 825,276 shares of the medical instruments supplier’s stock after purchasing an additional 166,677 shares during the period. Glaukos accounts for about 1.3% of Gilder Gagnon Howe & Co. LLC’s holdings, making the stock its 19th biggest holding. Gilder Gagnon Howe & Co. LLC owned 1.50% of Glaukos worth $123,742,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Stifel Financial Corp lifted its stake in Glaukos by 37.7% in the third quarter. Stifel Financial Corp now owns 4,230 shares of the medical instruments supplier’s stock valued at $551,000 after buying an additional 1,157 shares during the last quarter. Barclays PLC raised its position in Glaukos by 394.4% in the 3rd quarter. Barclays PLC now owns 89,699 shares of the medical instruments supplier’s stock valued at $11,686,000 after purchasing an additional 71,556 shares during the last quarter. Sanctuary Advisors LLC acquired a new stake in Glaukos during the 3rd quarter worth $258,000. Tidal Investments LLC boosted its stake in Glaukos by 83.1% during the 3rd quarter. Tidal Investments LLC now owns 14,908 shares of the medical instruments supplier’s stock worth $1,942,000 after purchasing an additional 6,767 shares during the period. Finally, Franklin Resources Inc. grew its position in Glaukos by 80.1% during the 3rd quarter. Franklin Resources Inc. now owns 15,621 shares of the medical instruments supplier’s stock worth $2,031,000 after purchasing an additional 6,948 shares during the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Price Performance

GKOS stock opened at $96.62 on Friday. The company has a market cap of $5.47 billion, a price-to-earnings ratio of -33.67 and a beta of 0.88. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The firm has a 50 day moving average of $102.37 and a 200-day moving average of $130.12. Glaukos Co. has a 12-month low of $77.91 and a 12-month high of $163.71.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The firm had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. As a group, equities analysts expect that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Piper Sandler decreased their target price on shares of Glaukos from $180.00 to $165.00 and set an “overweight” rating for the company in a research note on Tuesday, April 15th. Truist Financial decreased their price objective on Glaukos from $185.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, April 11th. Stifel Nicolaus boosted their target price on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Wells Fargo & Company upped their price target on Glaukos from $153.00 to $160.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Finally, Needham & Company LLC lifted their price objective on shares of Glaukos from $149.00 to $176.00 and gave the company a “buy” rating in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Glaukos currently has an average rating of “Moderate Buy” and an average target price of $156.17.

Insider Buying and Selling at Glaukos

In related news, CFO Alex R. Thurman sold 1,520 shares of the business’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the transaction, the chief financial officer now owns 53,431 shares of the company’s stock, valued at approximately $5,708,568.04. The trade was a 2.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.